In a second trial ( NCT@ ) , subjects received control or one of @ tetravalent HPV-@ / @/@/@ vaccines formulated with different adjuvant systems ( AS@ , AS@ or AS@ ) , administered on different schedules ( M@ ,@,@ or M@ ,@ or M@ ,@ ) .